A new marker for the detection of insulin resistance PDF Print E-mail
Titration of the circulating domain of IRAP

Introductioninsulinoresistance.jpg

Type 2 diabetes touches 8% and insulin resistance 20% of the population of industrialised countries. The prevalance of these two pathologies is constantly increasing, in particular in emerging countries. They represent major risk factors for morbidity and cardiovascular mortalities and in such a sense represent a major problem for public healthcare. The detection of insulin resistance would enable a strategy centred on prevention, for an affliction where the social and economic costs are growing incessantly (by means of an example, the global cost of diabetes healthcare has been estimated at 132 billion dollars in the United States in 2002).

Services and Product Offerings

Our offering centres on a diagnostic method based on the titration of the circulating domain named IRAPe of the IRAP protein (insulinregulated AminoPeptidase). IRAP protein is a transmembrane protein which colocolises with the glucose trnasporter GLUT4.

The translocation of GLUT4 to the plasmic membrane allows the capture of glucose and is regulated by insulin. At the moment the GLUT4 is inserted in the plasmic membrane, the extracellular domain of IRAP (IRAPe) is cleaved and secreted in the blood.

Where insulin resistance occurs, the translocation of GLUT4 and IRAP is reduced, and as a result, so is the secretion of IRAPe in the blood. The plasmatic concentration of IRAPe is therefore inversely proportional to the degree of insulin resistance.

schemainsulinuk.jpg

ELISA, IRMA and ICMA testing kits are currently in development.

We have already developed:

  • 5 monoclonal antibodies targeting different IRAPe epitopes
  • Recombinant human IRAPe
  • pecific ligands that have been radioactively marked
  • An ELISA prototype
schema2insulinuk.jpg

Benefits

Our method is the first simple, specific and quantitative detection system for a direct marker of insulin resistance (IRAPe) in the blood.

The detection of IRAPe as well as the monoclonal antibodies and ligands are patented.

Applications

• Detection of insulin resistance and type 2 diabetes
• Longterm analysis of insulin resistance and diabetes

References

[1] Maianu, L. et al. (2001) Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J Clin Endocrinol Metab 86:5450-5456.
[2] Keller, S.R. (2004) Role of the insulin-regulated aminopeptidase IRAP in insulin action and diabetes. Biol Pharm Bull 27:761-764.
[3] Keller, S.R. (2003) The insulin-regulated aminopeptidase: a companion and regulator of GLUT4. Front Biosci 8:s410-420.
[4] Keller, S.R. et al. (2002) Mice deficient in the insulinregulated membrane aminopeptidase show substancial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis. J Biol Chem 277:
17677-17686.

Contact
Véronique SENDRA
+33 (0)4 76 00 78 30
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 

TECHNOLOGY FOCUS

TESTIMONIALS

"The small animal optical imaging platform has worked on several projects for our company". Corinne Devaux, Nanobiotix
Read more...